Advertisement

Topics

Expert Addresses Abiraterone Versus Docetaxel in Castrationsensitive Prostate Cancer

13:35 EST 5 Mar 2018 | OncLive

Julie Graff, MD, shares her insight on pivotal trials exploring abiraterone acetate (Zytiga) and docetaxel in this in patients with castration-sensitive prostate cancer.

Original Article: Expert Addresses Abiraterone Versus Docetaxel in Castrationsensitive Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "Expert Addresses Abiraterone Versus Docetaxel in Castrationsensitive Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement